BioRestorative Therapies, Inc. (BRTX) Dividend History

Company News

• BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease

  BioRestorative Therapies presented promising preliminary data from its ongoing Phase 2 clinical trial of BRTX-100, an autologous stem cell therapy for chronic lumbar disc disease. The data showed significant improvements in pain and function for a majority of subjects, with a favorable safety profile.

  GlobeNewswire Inc.
• Should New Investors Buy Penny Stocks?

  Why New Investors Should Look Into Investing in Penny Stocks Penny stocks… The post Should New Investors Buy Penny Stocks? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

  PennyStocks

  Featured Companies: LGVN STSS
• Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Tops Revenue Estimates

  Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of -3.92% and 16.67%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research
• Dominari Holdings And 2 Other Stocks Under $3 Insiders Are Buying

  The Dow Jones index closed lower by over 400 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Dominari Holdings The Trade: Dominari Holdings Inc (NASDAQ: DOMH) President Kyle Michael Wool acquired a total of 8,500 shares an average price of $2.99. To acquire these shares, it cost around $25,390. What’s Happening: ...

  Benzinga

  Featured Companies: DOMH